Overview

Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC

Status:
Active, not recruiting

Trial end date:
2022-07-26

Target enrollment:

Participant gender:

Summary

This study looks at patients with advanced lung cancer. Participants in this study will be randomized into two groups. The first group will have radiation plus a drug (pembrolizumab). The second group will have only the drug (pembrolizumab). Tumors of participants will be measured to see if the addition of radiation changes the growth of the tumor compared to the drug alone.

Phase:

Phase 2

Details

Lead Sponsor:

Case Comprehensive Cancer Center

Treatments:

Pembrolizumab